Clinical trials
Completed Phase 4 trials in Hong Kong
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
125 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 10 |
| 2007 | 7 |
| 2008 | 8 |
| 2009 | 6 |
| 2010 | 11 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 14 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 125 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chinese University of Hong Kong | 25 |
| The University of Hong Kong | 23 |
| Hoffmann-La Roche | 7 |
| Novartis Pharmaceuticals | 7 |
| Sanofi | 6 |
| Bayer | 4 |
| GlaxoSmithKline | 4 |
| Boehringer Ingelheim | 3 |
| Pfizer | 3 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 13 |
| Hepatitis B, Chronic | 8 |
| Kidney Failure, Chronic | 7 |
| Arthritis, Rheumatoid | 6 |
| Diabetes Mellitus | 6 |
| Lupus Erythematosus, Systemic | 4 |
| Postoperative Pain | 4 |
| Renal Insufficiency | 4 |
| Acute Pain | 3 |
| Coronary Artery Disease | 3 |
Trials
Showing 1 to 25 of 125. Each trial links to its page on Pharma Observatory.
25 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.